Topline Ad­cetris da­ta in blood can­cer could mean new in­di­ca­tion for Pfiz­er

Pfiz­er is gun­ning for an eighth in­di­ca­tion for its Take­da-part­nered an­ti­body drug con­ju­gate Ad­cetris fol­low­ing pos­i­tive Phase III da­ta in blood can­cer.

Topline da­ta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER